TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04798313
Drug: Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
Study: NCT03574597
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Study: NCT00765232
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Study: NCT00765232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Study: NCT00038051
Drug: Hum-195/rGel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
Study: NCT00057551
Drug: Medication Only
Approvals — FDA: no, EMA: no, PMDA: no
Description: antidepressant medication
Study: NCT00960180
Drug: MR1817
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00960180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01319266
Drug: Hydrocodone Bitartrate extended-release tablet
Normalized name: hydrocodone bitartrate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
Study: NCT00045305
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antimetabolite
Study: NCT00045305
Drug: Photopheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psoralens
Study: NCT00695188
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration Escalating dose (15, 20, 25 mg)
Study: NCT00695188
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg oral administration
Study: NCT03693807
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Please see Detailed Description.
Study: NCT03693807
Drug: Anti-EGFR (Panitumumab or Cetuximab)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please see Detailed Description.
Study: NCT00622700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet Oral administration
Study: NCT01602185
Drug: Placebo (lactose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Study: NCT01469585
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg orally at the start of cycle 3 (study day 57) for 28 days.
Study: NCT00942266
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00942266
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04029090
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
Study: NCT04029090
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
Study: NCT04029090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
Study: NCT03173625
Drug: AC-076 for s.c. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
Study: NCT03173625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9% w/v sodium chloride solution
Study: NCT01199315
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule, Moderate Release
Study: NCT01199315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT03788863
Drug: Diflucortolone valerate (BAY866146)
Normalized name: diflucortolone valerate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow clinical administration
Study: NCT00532714
Drug: Irinotecan plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period).
Study: NCT01962870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00210379
Drug: intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00227617
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.
Study: NCT04274894
Drug: AndroGel 1.62%
Normalized name: Androgel 1.62% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel 1.62% was packaged in pump bottles with quantities sufficient to accommodate study design and could have been dose adjusted between a minimum of 20.25 mg of T (1 pump actuation) and a maximum of 81.0 mg of testosterone (4 pump actuations). For the first study drug administration at the Day 1 Visit, and also at Week 2, Week 4, Week 16 ambulatory blood pressure monitoring (ABPM,) and End of Treatment Visits, participants applied the study drug while on site so that the site staff could observe the proper administration of study drug. If participants forgot to apply their AndroGel 1.62% dose at their regularly scheduled dosing time, they were to take the next dose at the next dosing time.
Study: NCT02259738
Drug: Shuxuening injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00329329
Drug: satraplatin and capecitabine
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: satraplatin and capecitabine dose escalated per the dosing scheme
Study: NCT04475432
Drug: TP-03, 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Study: NCT01353781
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
Study: NCT00737685
Drug: cyclophosphamide, fludarabine , thymoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
Study: NCT00579280
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02675322
Drug: Danlou Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
Study: NCT01524497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
Study: NCT02852824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01012063
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
Study: NCT03347396
Drug: BIVV009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutimlimab was administered as intravenous (IV) infusion.
Study: NCT01706666
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03395600
Drug: B125S5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
Study: NCT02595346
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples.
Study: NCT00405158
Drug: Anti-pyretic medication, paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01827982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be given as a single oral dose.
Study: NCT03951259
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pills are made identical to the investigating SM934 in appearance.
Study: NCT03287232
Drug: Prasterone 6.5 mg (0.50%) Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Study: NCT00031486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
Study: NCT02600494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03056729
Drug: BIIB076
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as single intravenous (IV) infusion
Study: NCT03056729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as single IV infusion
Study: NCT03310580
Drug: AR-13324 Ophthalmic Solution 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study: NCT03310580
Drug: AR-13324 Ophthalmic Solution 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study: NCT03310580
Drug: AR-13324 Ophthalmic Solution Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to each eye, once daily (QD) in the evening (PM) for 28 days
Study: NCT03477266
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy identical tablets to mouthly dissolving mosapride tablets
Study: NCT01172002
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks.
Study: NCT00733980
Drug: GSK561679
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679
Study: NCT00977665
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet for 48 weeks
Study: NCT00014547
Drug: BBR 3464
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00816855
Drug: docetaxel, cisplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly
Study: NCT00554138
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dd for 7-10 days
Study: NCT00554138
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 dd 20 mg for 7-10 days
Study: NCT03797521
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo oral capsules
Study: NCT01039610
Drug: GSK945237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose detailed in Arm description
Study: NCT01039610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT00664599
Drug: Cytotoxic Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
Study: NCT00799409
Drug: Placebo/ CONCERTA (methylphenidate HCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
Study: NCT00799409
Drug: CONCERTA (methylphenidate HCl) / Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
Study: NCT00562640
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
Study: NCT02175355
Drug: High dose of Micardis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02175355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04232683
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill given preoperatively
Study: NCT03263611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intradiscal injection
Study: NCT03263611
Drug: AMG0103
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intradiscal injection
Study: NCT01441284
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01823224
Drug: IV tylenol 1000mg and 2 oral capsule sugar pills
Normalized name: Tylenol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group.
Study: NCT02658864
Drug: lafutidine
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of different doses, sex and medication conditions
Study: NCT04512066
Drug: RO6889450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral RO6889450 QD.
Study: NCT04512066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo QD.
Study: NCT02792465
Drug: CFI-402257
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00243880
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
Study: NCT03260868
Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection.
Study: NCT02771743
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02771743
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01573403
Drug: DLBS2411
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
Study: NCT01573403
Drug: Placebo DLBS2411
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo caplets of DLBS2411, once daily
Study: NCT02931526
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
Study: NCT01877785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MHAA4549A
Study: NCT00415519
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT00415519
Drug: Placebo of MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT00886106
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
Study: NCT03443895
Drug: AEF0117 oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6, 2 and 6mg of AEF0117
Study: NCT03443895
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule
Study: NCT01473303
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01473303
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02141217
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
Study: NCT04202978
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine:850mg/m2 P.O ,bid ,d1-d14
Study: NCT03235726
Drug: CCI15106
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Study: NCT03235726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
Study: NCT02361619
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: probe
Study: NCT02361619
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: probe
Study: NCT02361619
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perpetrator
Study: NCT01022151
Drug: Placebo [group P]
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive intravenous injection of 0.2 mL/kg of saline 0.9%L \[group P\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study: NCT00481572
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: titrated norepinephrine over a period of 48 hrs
Study: NCT04697277
Drug: Antibiotic prophylaxis timing (before skin incision and after cord clamping) for caesarean section
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02317926
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02317926
Drug: Levothyroxine Plus Liothyronine
Normalized name: LEVOTHYROXINE/LIOTHYRONINE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02317926
Drug: Desiccated Thyroid Extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01673399
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00759798
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
Study: NCT03258398
Drug: eFT508
Approvals — FDA: no, EMA: no, PMDA: no
Description: eFT508 will be taken orally (PO) twice a day (bid).
Study: NCT01779050
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162121
Drug: Ketorolac 30mg
Normalized name: ketorolac 30 MG
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00109772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules taken one time per day
Study: NCT01989754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule taken orally (by mouth) once daily for 156 weeks
Study: NCT02516150
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
Study: NCT00618995
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets for each of the interventions once daily for 7 days
Study: NCT01779050
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00385606
Drug: rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no